When patients were divided into subgroups by tumor PD‐L1 expression level, we observed a significant OS benefit in the PD‐L1 1%–49% group and a fair OS benefit in the <1%/indeterminate and ≥ 50% groups. The gene discussed is CD274; the disease is neoplasm.